In Phase C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment until eventually disease progression or the participants are unable to tolerate the study drugs. 88 These preclinical studies deliver paradigms for long run clinical trials in AML, https://abbv-744-combination-ther81245.theblogfairy.com/31282692/a-review-of-abbv-744-in-combination-with-immunotherapy